Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone

Autores
Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; Latella, Antonio; Zubizarreta, Pedro
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease.
Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Rosso, Diego. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pollono, Daniel. No especifica;
Fil: Rey, Guadalupe. No especifica;
Fil: Lagomarsino, Eduardo. No especifica;
Fil: Latella, Antonio. No especifica;
Fil: Zubizarreta, Pedro. No especifica;
Materia
Histiocytosis
Indomethacin Therapy
Pediatric
Bone Langerhans Cell Histiocytosis
Outcome
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/29381

id CONICETDig_ef0edf0b04710a31c40781b96a36369c
oai_identifier_str oai:ri.conicet.gov.ar:11336/29381
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin aloneBraier, JorgeRosso, DiegoPollono, DanielRey, GuadalupeLagomarsino, EduardoLatella, AntonioZubizarreta, PedroHistiocytosisIndomethacin TherapyPediatricBone Langerhans Cell HistiocytosisOutcomehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease.Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Rosso, Diego. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pollono, Daniel. No especifica;Fil: Rey, Guadalupe. No especifica;Fil: Lagomarsino, Eduardo. No especifica;Fil: Latella, Antonio. No especifica;Fil: Zubizarreta, Pedro. No especifica;Lippincott Williams2014-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/29381Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; et al.; Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone; Lippincott Williams; Journal Of Pediatric Hematology Oncology; 36; 5; 7-2014; e280-e2841077-4114enginfo:eu-repo/semantics/altIdentifier/doi/10.1097/MPH.0000000000000165001info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/jpho-online/pages/articleviewer.aspx?year=2014&issue=07000&article=00022&type=abstractinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:08:31Zoai:ri.conicet.gov.ar:11336/29381instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:08:32.246CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
title Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
spellingShingle Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
Braier, Jorge
Histiocytosis
Indomethacin Therapy
Pediatric
Bone Langerhans Cell Histiocytosis
Outcome
title_short Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
title_full Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
title_fullStr Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
title_full_unstemmed Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
title_sort Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
dc.creator.none.fl_str_mv Braier, Jorge
Rosso, Diego
Pollono, Daniel
Rey, Guadalupe
Lagomarsino, Eduardo
Latella, Antonio
Zubizarreta, Pedro
author Braier, Jorge
author_facet Braier, Jorge
Rosso, Diego
Pollono, Daniel
Rey, Guadalupe
Lagomarsino, Eduardo
Latella, Antonio
Zubizarreta, Pedro
author_role author
author2 Rosso, Diego
Pollono, Daniel
Rey, Guadalupe
Lagomarsino, Eduardo
Latella, Antonio
Zubizarreta, Pedro
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Histiocytosis
Indomethacin Therapy
Pediatric
Bone Langerhans Cell Histiocytosis
Outcome
topic Histiocytosis
Indomethacin Therapy
Pediatric
Bone Langerhans Cell Histiocytosis
Outcome
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease.
Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Rosso, Diego. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pollono, Daniel. No especifica;
Fil: Rey, Guadalupe. No especifica;
Fil: Lagomarsino, Eduardo. No especifica;
Fil: Latella, Antonio. No especifica;
Fil: Zubizarreta, Pedro. No especifica;
description This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease.
publishDate 2014
dc.date.none.fl_str_mv 2014-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/29381
Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; et al.; Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone; Lippincott Williams; Journal Of Pediatric Hematology Oncology; 36; 5; 7-2014; e280-e284
1077-4114
url http://hdl.handle.net/11336/29381
identifier_str_mv Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; et al.; Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone; Lippincott Williams; Journal Of Pediatric Hematology Oncology; 36; 5; 7-2014; e280-e284
1077-4114
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1097/MPH.0000000000000165001
info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/jpho-online/pages/articleviewer.aspx?year=2014&issue=07000&article=00022&type=abstract
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Lippincott Williams
publisher.none.fl_str_mv Lippincott Williams
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270048941506560
score 13.13397